RT Journal Article
SR Electronic
T1 Serosurvey of SARS-COV-2 at a large public university
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.05.23285494
DO 10.1101/2023.02.05.23285494
A1 Hou, Ching-Wen
A1 Williams, Stacy
A1 Taylor, Kylee
A1 Boyle, Veronica
A1 Bobbett, Bradley
A1 Kouvetakis, Joseph
A1 Nguyen, Keana
A1 McDonald, Aaron
A1 Harris, Valerie
A1 Nussle, Benjamin
A1 Scharf, Phillip
A1 Jehn, Megan
A1 Lant, Timothy
A1 Magee, Mitch
A1 Chung, Yunro
A1 Labaer, Joshua
A1 Murugan, Vel
YR 2023
UL http://medrxiv.org/content/early/2023/02/07/2023.02.05.23285494.abstract
AB Arizona State University (ASU) is one the largest universities in the United States, with more than 79,000 students attending in-person classes. We conducted a seroprevalence study from September 13-17, 2021 to estimate the number of people in our community with SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. Participants provided their age, gender, race, status (student or employee), and general COVID-19 health-related information like previous exposure and vaccination status. The seroprevalence of the anti-receptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semi-quantitative chemiluminescent immunoassay. The seroprevalence for anti-nucleocapsid (NC) was 20%. In addition, individuals with previous natural COVID infection plus vaccination had higher anti-RBD antibody levels compared to those who had vaccination only or infection only. Individuals who had a breakthrough infection had the highest anti-RBD antibody levels.Accurate estimates of the cumulative incidence of SARS-CoV-2 infection can inform the development of university risk mitigation protocols such as encouraging booster shots, extending mask mandates, or reverting to online classes. It could help us to have clear guidance to take action at the first sign of the next surge as well, especially since there is a surge of COVID subvariant infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Arizona State University Knowledge EnterpriseAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Arizona State University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript